Humanin was originally identified in research on Alzheimer’s disease, found to have a protective effect against a specific toxic protein mechanism studied in that context — a different discovery story than MOTS-c’s, even though the two compounds are frequently grouped together in community discussion as “mitochondrial peptides.”

The Neuroprotective Research Thread

Humanin’s original and still most substantial research base is in neuroprotection and cellular stress response, studied mostly in cell culture and animal models relevant to neurodegenerative disease — not primarily in the metabolic or longevity framing it’s often sold under now.

“They get bundled together because they’re both mitochondrial-derived. The actual research behind each one is answering a different question.”

— a neurobiology researcher who reviewed the comparative literature for this piece

Where the Longevity Framing Comes From

Circulating humanin levels have been observed to decline with age in some human studies, which is the correlational basis for longevity marketing — an association, not evidence that supplementation reverses or slows anything.

Grouping Risks Losing the Actual Science

Treating humanin and MOTS-c as interchangeable “mitochondrial peptides” obscures that each has its own distinct mechanism, disease context, and evidence gaps — flattening two different research stories into one marketing category.